In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria

Pusztai-Markos, Zs.; Pranada, F.

doi:10.1007/bf02014140

Cited by 3 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Al though adequate clinical documentation is not yet available, our study illustrates that the drug has good activity against P. aeru ginosa and A. calcoaceiicus, agreeing with the findings of others [1,5,6,9], Tobramy cin, however, remains the most active agent against P. aeruginosa, with no resis tant strains in our collection, even though the drug has been in clinical use in our country for many years.…”

Section: Discussionsupporting

confidence: 76%

Pseudomonas aeruginosa and Acinetobacter calcoaceticus: In vitro Susceptibility of 150 Clinical Isolates to Five β-Lactam Antibiotics and Tobramycin

Dibb¹,

Kjellevold²,

Digranes³

1983

Chemotherapy

View full text Add to dashboard Cite

The in vitro activities of azlocillin, carbenicillin, ceftriaxone, piperacillin, N-formimidoyl thienamycin (N-f thienamycin) and tobramycin have been compared against clinical isolates of Pseudomonas aeruginosa (n = 100) and Acinetobacter calcoaceticus (n = 50). An agar dilution method was employed for measurement of minimal inhibitory concentration (MIC). Tobramycin was the most active drug against P. aeruginosa (MIC≤2 mg/l). Of the β-lactam antibiotics, N-f thienamycin showed the highest activity, and carbenicillin was least active. Both N-f thienamycin and tobramycin were highly active against A. calcoaceticus (MIC≤ mg/l), although one isolate was resistant to tobramycin (MIC > 16 mg/l). The other drugs were only moderately active against A. calcoaceticus.

show abstract

Section: Discussionsupporting

confidence: 76%

Pseudomonas aeruginosa and Acinetobacter calcoaceticus: In vitro Susceptibility of 150 Clinical Isolates to Five β-Lactam Antibiotics and Tobramycin

Dibb¹,

Kjellevold²,

Digranes³

1983

Chemotherapy

View full text Add to dashboard Cite

show abstract

Antibacterial Activity of Imipenem: The First Thienamycin Antibiotic

Kropp

Gerckens

Sundelof

et al. 1985

Clinical Infectious Diseases

115

View full text Add to dashboard Cite

Imipenem/Cilastatin

Clissold¹,

Todd²,

Campoli-Richards³

1987

Drugs

119

View full text Add to dashboard Cite

Imipenem is the first available semisynthetic thienamycin and is administered intravenously in combination with cilastatin, a renal dipeptidase inhibitor that increases urinary excretion of active drug. In vitro studies have demonstrated that imipenem has an extremely wide spectrum of antibacterial activity against Gram-negative and Gram-positive aerobic and anaerobic bacteria, even against many multiresistant strains of bacteria. It is very potent against species which elaborate beta-lactamases. Imipenem in combination with equal doses of cilastatin has been shown to be generally well tolerated and an effective antimicrobial for the treatment of infections of various body systems. It is likely to be most valuable as empirical treatment of mixed aerobic and anaerobic infections, bacteraemia in non-neutropenic patients and serious hospital-acquired infections.

show abstract

In vitro activity of N-formimidoyl-thienamycin in comparison to that of moxalactam and cefotaxime against gentamicin-resistant gram-negative bacteria

Cited by 3 publications

References 7 publications

<i>Pseudomonas aeruginosa</i> and <i>Acinetobacter calcoaceticu</i><i>s</i>: In vitro Susceptibility of 150 Clinical Isolates to Five <i>β</i>-Lactam Antibiotics and Tobramycin

<i>Pseudomonas aeruginosa</i> and <i>Acinetobacter calcoaceticu</i><i>s</i>: In vitro Susceptibility of 150 Clinical Isolates to Five <i>β</i>-Lactam Antibiotics and Tobramycin

Antibacterial Activity of Imipenem: The First Thienamycin Antibiotic

Imipenem/Cilastatin

Contact Info

Product

Resources

About